The DOI matches its Crossref record.
Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty
Open accessAbstract
Background —Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. The present study aimed to determine the effect of cilostazol on restenosis after PTCA. Methods and Results —Two hundred eleven patients with 273 lesions who underwent successful PTCA were randomly assigned to the cilostazol (200 mg/d) group or the aspirin (250 mg/d) control group. Administration of cilostazol was initiated immediately after PTCA and continued for 3 months of follow-up. Quantitative coronary angiography was performed before PTCA and after PTCA and at follow-up. Reference diameter, minimal lumen diameter, and percent diameter stenosis (DS) were measured by quantitative coronary angiography. Angiographic restenosis was defined as DS at follow-up >50%. Eligible follow-up angiography was performed in 94 patients with 123 lesions in the cilostazol group and in 99 patients with 129 lesions in the control group. The baseline characteristics and results of PTCA showed no significant difference between the 2 groups. However, minimal lumen diameter at follow-up was significantly larger (1.65±0.55 vs 1.37±0.58 mm; P <0.0001) and DS was significantly lower (34.1±17.8% vs 45.6±19.3%; P <0.0001) in the cilostazol group. Restenosis and target lesion revascularization rates were also significantly lower in the cilostazol group (17.9% vs 39.5%; P <0.001 and 11.4% vs 28.7%; P <0.001). Conclusions —Cilostazol significantly reduces restenosis and target lesion revascularization rates after successful PTCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Medical treatment of peripheral arterial disease and claudication
Hiatt, W. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442108 · Cited by 1,121
Genetics of blood lipids among ∼300,000 multi-ethnic participants of the Million Veteran Program
Global Lipids Genetics Consortium, Klarin, D., Myocardial Infarction Genetics (MIGen) Consortium, The Geisinger-Regeneron DiscovEHR Collaboration, Program, T. V. M. V., Damrauer, S. M., Cho, K., Sun, Y. V., Teslovich, T. M., Honerlaw, J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0222-9 · Cited by 625
Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels
Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G., & Hess, O. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011364 · Cited by 532
McQuaid, K. R., & Laine, L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.10.039 · Cited by 409
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Metadata
- Authors
- Tsuchikane, E., Fukuhara, A., Kobayashi, T., Kirino, M., Yamasaki, K., Kobayashi, T., Izumi, M., Otsuji, S., Tateyama, H., Sakurai, M., & Awata, N.
- Venue
- Circulation
- Published
- 1999-07-06
- Volume
- 100
- Issue
- 1
- Pages
- 21-26
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993157664
- Cited by
- 184
- References
- 0
- FWCI
- 17.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty. https://app.cochat.ai/papers/10.1161/01.cir.100.1.21
- The paper
- Tsuchikane, E., Fukuhara, A., Kobayashi, T., Kirino, M., Yamasaki, K., Kobayashi, T., Izumi, M., Otsuji, S., Tateyama, H., Sakurai, M., & Awata, N. (1999). Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty. Circulation. https://doi.org/10.1161/01.cir.100.1.21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.